Skip to content
Print-ready dossier — use your browser's print dialog to save as PDF.

AESKULISA® ß2-Glyco-GM

Model 3206 · Aesku.Diagnostics GmbH & Co. KG · DI 04250289500869

MSVSystem,Test,Antibodies,B2 - Glycoprotein I (B2 - Gpi) · Class II · 21 CFR 866.5660

UDILibrary device dossier · generated 2026-09-12 · sources: FDA GUDID, openFDA (recalls, MAUDE, 510(k)/PMA), FDA Data Dashboard (inspections, compliance actions), 510(k) summary documents.

Recall history (0)

No recalls linked in the loaded window.

Adverse-event reports — MAUDE (0)

Caveat (required reading): MAUDE report counts cannot be used to compute incidence rates or compare device safety. Reporting is incomplete, duplicated, and spikes with publicity; there is no denominator of devices in use. The peer line is a reporting baseline (average device in the same product code), not a risk measure.

01112023-03: 0 reports for this device; peer average 1/device03
Monthly adverse-event reports for this device versus the product-code average.
MonthThis device (reports)Product-code average (reports per device)
2023-0301
This device (reports/month)Average device in MSV (reports/device/month)

Regulatory clearances

  • None linked in the loaded window.

Manufacturer compliance record — Aesku.Diagnostics GmbH & Co. KG

  • VAI 2017-03-02 Aesku Group GmbH & Co. KG · 2 citations